The Duhring chamber assay for corticosteroid atrophy.
A new human model for the evaluation of the atrophogenicity of topical corticosteroids is proposed. Formulated corticosteroids (creams and ointments) were applied occlusively to normal forearm skin of human volunteers for 3 weeks using Duhring chambers. Visible atrophy and telangiectasia were rated under a stereomicroscope on a histologically validated five-point scale. There was a close correlation between the parameters of atrophy and telangiectasia. Atrophogenicity varied considerably among the tested corticosteroids, ranging from none (1% hydrocortisone) via moderate (0.1% betamethasone valerate) to very severe (0.05% clobetasol propionate). A dose-response relationship with exposure time and concentration of the corticosteroid could be demonstrated. Furthermore, the vehicle influenced the resulting atrophy and telangiectasia. Fatty ointments seem to pose less risk than oil in water creams.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000633:toxicity*; D001284:Atrophy / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D009823:Ointment Bases; D012867:Skin / Q000473:pathology*; D012882:Skin Tests / Q000379:methods*; D013684:Telangiectasis / Q000139:chemically induced
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D009823:Ointment Bases